Evidence map›Paper›PMID 29525934›Full record

ReviewCurrent atherosclerosis reports2018

Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.

Angelos D Karagiannis, Martin Liu, Peter P Toth, Shijia Zhao, Devendra K Agrawal, Peter Libby, Yiannis S Chatzizisis

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04338165 (Effect of Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography), which is not on this map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04338165 phase2unknown statusstarted 2021, after this paper: background citation

Effect of Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography : a Monocentric, Prospective, Randomized and Open-label Phase II Trial

Ran2021Enrolled66Registered outcomes6Posted comparisons0ConditionsAtherosclerotic Cardiovascular DiseaseArmsEvolocumab 140 MG/ML [Repatha]
PMID 28304224PMID 24625727PMID 10779454PMID 10704159PMID 11074073PMID 12163423PMID 12821539PMID 15136498PMID 21596324PMID 22176652PMID 22874078PMID 23347861other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 88 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. The Anti-Thrombotic Effects of PCSK9 Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Angelos D KaragiannisCardiovascular Biology and Biomechanics Laboratory, Cardiovascular Division, University of Nebraska Medical Center, 982265 Nebraska Medical Center, Omaha, NE, 68198, USA.
Martin LiuCardiovascular Biology and Biomechanics Laboratory, Cardiovascular Division, University of Nebraska Medical Center, 982265 Nebraska Medical Center, Omaha, NE, 68198, USA.
Peter P TothCGH Medical Center, Sterling, IL, and Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shijia ZhaoCardiovascular Biology and Biomechanics Laboratory, Cardiovascular Division, University of Nebraska Medical Center, 982265 Nebraska Medical Center, Omaha, NE, 68198, USA.
Devendra K AgrawalDepartment of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, USA.
Peter LibbyCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yiannis S ChatzizisisCardiovascular Biology and Biomechanics Laboratory, Cardiovascular Division, University of Nebraska Medical Center, 982265 Nebraska Medical Center, Omaha, NE, 68198, USA. ychatzizisis@icloud.com.
University of Nebraska Medical Center · USBrigham and Women's Hospital · USCreighton University · USJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewClinical trials with PCSK9 inhibitors have shown a robust decrease in plasma LDL levels and a significant reduction in the incidence of cardiovascular atherosclerotic events. However, the role of PCSK9 in atherosclerosis is not well investigated and it remains unclear whether PCSK9 inhibition has direct, LDL-independent, anti-atherosclerotic effects. This review outlines the molecular pathways and targets of PCSK9 in atherosclerosis and summarizes the experimental and clinical data supporting the anti-atherosclerotic (pleiotropic) actions of PCSK9 inhibitors. RECENT

findingsPCSK9 is expressed by various cell types that are involved in atherosclerosis (e.g., endothelial cell, smooth muscle cell, and macrophage) and is detected inside human atherosclerotic plaque. Preclinical studies have shown that inhibition of PCSK9 can attenuate atherogenesis and plaque inflammation. Besides increasing plasma LDL, PCSK9 appears to promote the initiation and progression of atherosclerosis. Inhibition of PCSK9 may confer atheroprotection that extends beyond its lipid-lowering effects.

Indexed as

PCSK9 InhibitorsAntibodies, MonoclonalAnticholesteremic AgentsAtherosclerosisCholesterol, LDLGene ExpressionHumansInflammationPlaque, AtheroscleroticProprotein Convertase 9RNA, Small InterferingVaccinesAntibodies, MonoclonalAnticholesteremic AgentsCholesterol, LDLPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9RNA, Small InterferingVaccinesAlirocumabAnti-atherosclerotic effectsAtherosclerosisEvolocumabInclisiranPCSK9 inhibitorsPleiotropic effectsProprotein convertase subtilisin/kexin 9

Identifiers

PMID29525934
OpenAlexW2793047794

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.